Shares of medical-device marker Edwards Lifesciences soared Monday, hitting an all-time high after positive results from testing of a device used for open-heart surgery. Over the weekend, the Irvine, Calif., company said transcatheter aortic-valve replacements using its “Sapien 3” valve produced better outcomes, including lower mortality rates and fewer strokes. The data were followed by a string of upgrades from Wall Street firms on Monday, including BTIG, which upgraded Edwards Lifesciences Corp. to buy from neutral. J.P. Morgan Chase also raised its price target for the company to $110 from $98, and said the company has “ample room for upside.” On Monday, Edwards Lifesciences set an all-time high of $104.94. Since hitting a 2016 low on Feb. 9, the company’s shares have soared nearly 16% compared with 11.2%, 10% for the S&P 500 and 14.1% for the Nasdaq Composite .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News